Welcome to our dedicated page for CURALEAF HLDGS news (Ticker: CURLF), a resource for investors and traders seeking the latest updates and insights on CURALEAF HLDGS stock.
Curaleaf Holdings, Inc. (CURLF) is a prominent international provider of consumer cannabis products, known for its mission to enhance lives by sharing and celebrating the power of the plant. It operates under various brands like Curaleaf, Select, Grassroots, JAMS, Find, and Zero Proof in the medical and adult-use markets. With operations in over 15 countries globally, Curaleaf focuses on quality, expertise, and accessibility in the cannabis industry.
Recently, Curaleaf announced a strategic acquisition of Northern Green Canada, a licensed Canadian cannabis producer with a focus on international market expansion. This move aligns with Curaleaf's vision of becoming a global cannabis company with a strong presence in North America, Europe, and Australasia. The acquisition of NGC provides Curaleaf with EU-GMP certification, enabling the company to strengthen its supply chain, improve margins, and extend its global footprint.
Under the leadership of Boris Jordan, Executive Chairman, and Matt Darin, CEO, Curaleaf continues to drive growth and innovation within the cannabis space. The company's commitment to delivering high-quality products and patient access remains a top priority in evolving markets and regulatory environments.
Curaleaf Holdings (CURLF) has announced the appointment of Michelle Bodner and Shasheen Shah to its Board of Directors, effective December 31, 2022. Bodner brings extensive experience in operations and executive coaching, having previously served in various roles within Curaleaf. Shah, a leadership development coach, will also add strategic insights to the board. With these additions, the board now has eight members, including four independent directors. This move aims to enhance governance as Curaleaf prepares for its 2023 initiatives.
Curaleaf Holdings announced a groundbreaking partnership between its Grassroots brand and Ganjier, launching a unique cannabis education program. This initiative aims to elevate the cannabis industry's standards through training for 100 nominated team members and external partners. The program incorporates a comprehensive online curriculum, culminating in an in-person training session in Humboldt, California. The Grassroots brand is operational in seven states and focuses on high-quality cannabis products, aligning with Curaleaf's commitment to cannabis education and professionalism.
Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) has announced its participation in investor conferences in December 2022. CEO Matt Darin will engage in a fireside chat at Cowen's 5th Annual Cannabis Conference on December 6, followed by a lunch panel at Stifel Canada's 3rd Annual Future of Healthcare Conference on December 7. Curaleaf is recognized as a leader in the cannabis sector, operating 144 dispensaries across 21 states and being the largest vertically integrated cannabis company in Europe. For more details, visit Curaleaf's Investor Relations website.
Curaleaf Holdings reported Q3 2022 revenue of $340 million, marking a 1% sequential increase and 7% year-over-year growth. The company achieved Adjusted EBITDA of $84 million, up 18% YoY, with a 24.7% margin. Despite a net loss of $51 million, improved cash flow of $60 million was generated. The company expanded its retail footprint to 137 locations and increased retail revenue by 16%. Recent acquisitions, including Four20 Pharma and Tryke, aim to strengthen market position.
Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) has announced its participation in several investor conferences in November 2022. The events include MJBizCon from November 15-18, where Curaleaf management will host investor meetings, and the CannaVest West Institutional Capital Forum from November 16-17, featuring keynote speeches by Executive Chairman Boris Jordan and CEO Matt Darin. Curaleaf operates in 21 states with 142 dispensaries and is recognized as a leader in the cannabis industry, focusing on consumer products and market expansion.
Curaleaf International announces significant findings from a clinical study on cannabidiol (CBD) treatment for Vestibulodynia (VBD), presented by Chief Scientific Officer Dr. Barbara Pacchetti at a medical cannabis conference on October 21-22, 2022. The study, involving 60 patients, demonstrated improved pain outcomes and muscular tone. Additionally, preclinical studies pointed to CBD's potential in treating psychiatric disorders and migraine pain. Curaleaf focuses on advancing scientific understanding of medical cannabis in collaboration with top academic institutions.
FAQ
What is the current stock price of CURALEAF HLDGS (CURLF)?
What is the market cap of CURALEAF HLDGS (CURLF)?
What is Curaleaf Holdings, Inc. known for?
Who are the key leaders at Curaleaf?
What recent acquisition has Curaleaf made?
Where does Curaleaf operate?
